Press "Enter" to skip to content

AbbVie halts late-stage trial for lung cancer drug Rova-T

AbbVie Inc said on Wednesday it had halted enrollment for a late stage trial of Rova-T as a second-line therapy for advanced small-cell lung cancer, following recommendations made by an independent data monitoring committee.

Original source:

Also Read:   Mexico reports 3,484 new coronavirus cases, 188 more deaths